Beaumont Financial Advisors LLC Purchases 48 Shares of Amgen Inc. (NASDAQ:AMGN)

Beaumont Financial Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,757 shares of the medical research company’s stock after purchasing an additional 48 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Amgen were worth $1,370,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Davidson Trust Co. increased its stake in Amgen by 11.3% in the fourth quarter. Davidson Trust Co. now owns 1,928 shares of the medical research company’s stock valued at $555,000 after acquiring an additional 195 shares during the last quarter. HTLF Bank bought a new position in Amgen in the fourth quarter valued at $8,771,000. Fidelis Capital Partners LLC increased its stake in Amgen by 26.7% in the fourth quarter. Fidelis Capital Partners LLC now owns 3,569 shares of the medical research company’s stock valued at $1,028,000 after acquiring an additional 753 shares during the last quarter. Obermeyer Wood Investment Counsel Lllp increased its stake in Amgen by 4.3% in the fourth quarter. Obermeyer Wood Investment Counsel Lllp now owns 4,087 shares of the medical research company’s stock valued at $1,177,000 after acquiring an additional 169 shares during the last quarter. Finally, Xponance Inc. increased its stake in Amgen by 3.5% in the fourth quarter. Xponance Inc. now owns 111,690 shares of the medical research company’s stock valued at $32,169,000 after acquiring an additional 3,726 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. UBS Group cut their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday. Oppenheimer restated an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Truist Financial restated a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Finally, Morgan Stanley dropped their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Stock Performance

Shares of AMGN opened at $268.93 on Friday. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a 50-day simple moving average of $276.90 and a two-hundred day simple moving average of $281.26. The firm has a market capitalization of $144.25 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 2.44 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the firm earned $4.09 earnings per share. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.35%. Amgen’s payout ratio is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.